Key result
Endothelin receptor antagonists have substantially expanded the therapeutic approach toward severe pulmonary arterial hypertension.
Why the study?
Does the use of endothelin receptor antagonists improve outcomes in patients with pulmonary arterial hypertension?
Does the use of endothelin receptor antagonists improve outcomes in patients with pulmonary arterial hypertension?
Endothelin receptor antagonists have become an important therapeutic option in the clinical management of severe pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
Solidifies endothelin receptor antagonists as a cornerstone therapy for severe pulmonary arterial hypertension;.
Pulmonary arterial hypertension (PAH) is a severe disease with marked morbidity and mortality for which therapeutic strategies have been limited. Basic research in vascular biology has implicated endothelin-1 (ET-1) and its receptors (ET(A) and ET(B)) in diverse preclinical models of PAH, and ET-1 has been shown to contribute significantly to PAH in human patients. Despite the complexity of roles of the ET receptors in the development or reversal of PAH in the laboratory, the introduction of endothelin receptor antagonists (ETRAs) to clinical medicine has substantially expanded our therapeutic approach toward severe PAH. This article briefly reviews preclinical data and the current status of ETRAs in the clinical management of PAH.
No takes yet. Share an insight, caveat, or question.
Steven H. Abman (2008) conducted a review in Pulmonary arterial hypertension (PAH). Endothelin receptor antagonists (ETRAs) was evaluated. Endothelin receptor antagonists have substantially expanded the therapeutic approach toward severe pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: